PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

PDS Biotechnology Corporation

B. Riley Securities analyst Mayank Mamtani maintained a Buy rating on PDS Biotechnology yesterday and set a price target of $3.00. The company’s sh...

B. Riley Securities Sticks to Their Buy Rating for PDS Biotechnology (PDSB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and P...

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and Praxis Precision Medicines (PRAX)

Pds Biotechnology (($PDSB)) has held its Q4 earnings call. Read on for the main highlights of the call. PDS Biotechnology’s latest earnings call st...

PDS Biotechnology Earnings Call Highlights Clinical Momentum

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. market, rose 0.16% on Thursday. The move followed news that Iran is draft...

Vanguard Total Stock Market ETF (VTI) Daily Update, 4/3/26?

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is drawing renewed attention from investors after attractin...

VTI Sees $2B in Net Flows – Why Investors Are Pouring Into This Vanguard ETF

The Vanguard Total Stock Market ETF ($VTI) tracks the broader U.S. stock market. The fund attracted strong investor interest recently, with about $...

VTI Sees $1B Inflows as Vanguard ETF Gains Momentum — 3/19/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, was down 1.1% at market open on Thursday. Investor sentimen...

Why Is the VTI ETF Down Today? Daily Snapshot – 3/12/26

Choosing between a mutual fund and an ETF can be tricky, even when both track the same index. Vanguard Total Stock Market Index Fund Admiral Shares...

Mutual Fund vs. ETF? Should You Buy VTSAX or VTI in 2026?

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.26% in pre-market hours on Tuesday. Overall, VTI ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PDSB	$0.96	+4.58%	1.27M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PDSB	$0.96	+4.6%	1.27M
3
4
5
6

PDSB

PDSB

Dividend Overview

Get PDS Biotechnology Corporation Data in Excel

Get PDS Biotechnology Corporation Data in Excel